Authors
Latest:
Lessons Learned from the Multichannel ShakeoutInnovation by itself won't solve the complex multichannel challenges pharmas face.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Access and Reimbursement for Adoptive T-Cell Transfer DrugsGroundbreaking treatment approaches call for innovative commercialization strategies.
Latest:
Drug Delivery’s Role in Improving Rural OutcomesIn the search for effective and efficient ways to bridge the urban/rural divide, technological advances are offering more and more solutions.
Latest:
Olivier Laureau, Servier: Free to Grow, InnovateFrench independent pharma Servier Group, led by president Olivier Laureau, is uniquely positioned to capitalize on new opportunities for expansion and stay true to its R&D and patient-focused mission.
Latest:
From Lab to Life: Improving Patient Lives through Community-based Healthcare and Decentralized Clinical TrialsIn Episode Three of the Syneos Health Dedicated Dialogue podcast series, we uncover how the proliferation of new digital health technologies, telemedicine and mobile nursing services are helping fuel novel clinical trials. These range from community-based studies, which are administered through PCPs, local health centers and outpatient facilities in lieu of academic research centers, to hybrid and fully virtual trials designed around patients in their homes, with or without a synthetic control arm replacing patients on placebos. Additionally, we share new insights about how trial sponsors discovering new ways to engage participants, enhance data capture and devise pathways to put patients at the center of clinical trials across the biopharmaceutical product development continuum.
Latest:
Master Data Management 2.0Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.
Latest:
The Top Barriers to Patient PersistenceAnd ways pharma can help overcome these hurdles-and boost compliance rates across the full durations of treatment
Latest:
AI in the Medical Domain: Not a Quick FixDanish Gupta discuss the current strengths and weaknesses of artificial intelligence applications in life sciences.
Latest:
Spotlight on Mexico: Healthcare under AMLO—One Year OnAs we near the end of the first year of Mexican president Andrés Manuel López Obrador's six-year term, Rachel Howard caught up with local expert Dr Xavier Tello to make sense of the latest changes in the healthcare system and consider what they mean for pharma manufacturers wishing to enter the Mexican market.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Revolutionizing Clinical Trials Through Real-Time Data Capture and AnalyticsThis article discusses real-time data capture and analytics in clinical trials.
Latest:
Access Headwinds Reach IDN Specialty Pharmacy ProgramsInsights from Partnering with IDNs: Biopharma Strategy Summit.
Latest:
Compliance in China: Key ConsiderationsDavid Simon outlines the procedures to manage anti-corruption risk that life sciences companies should consider before doing business in China.
Latest:
Healthcare Reform in Ukraine Opens New Horizons for InvestorsAs the Ukranian healthcare market opens up to more public and private competition, it will become more attractive for investors - both Ukrainian and foreign, write Lana Sinichkina and Anna Zorya.
